Potassium voltage-gated channel subfamily Q (KCNQ)

The Potassium voltage-gated channel subfamily Q, commonly referred to as the Kv7 family, comprises five members (KCNQ1-KCNQ5) that are vital regulators of cellular excitability across the nervous, cardiac, and muscular systems (UniProt, 2024). In neurons, KCNQ2 and KCNQ3 subunits form heteromeric channels that produce the M-current, a subthreshold potassium current that limits repetitive action potential firing and stabilizes the resting membrane potential (IUPHAR/BPS, 2024). KCNQ1 is predominantly expressed in the heart, where it associates with KCNE1 to facilitate the slow delayed rectifier potassium current (IKs) necessary for proper cardiac repolarization (StatPearls, 2023). Mutations in these channels are linked to severe pathologies, including Benign Familial Neonatal Epilepsy (KCNQ2/3), Long QT syndrome type 1 (KCNQ1), and non-syndromic deafness (KCNQ4) (Miceli et al., 2018). Pharmacologically, KCNQ channels are targeted by openers like retigabine to treat epilepsy by reducing neuronal hyperactivity, though clinical use has been limited by side effects such as tissue discoloration and urinary retention (FDA, 2013). Current drug discovery efforts are focused on developing subtype-selective modulators to improve safety profiles and expand therapeutic applications into neuropathic pain and mood disorders (Gunthorpe et al., 2012).

Other names

Kv7 channel familyM-channelKQT-like subfamilyVoltage-gated potassium channel subunit Kv7

Drugs targeting this subfamily typically act as positive allosteric modulators (openers) to increase potassium efflux and hyperpolarize the cell membrane, thereby reducing excitability, or as inhibitors (blockers) to decrease potassium efflux and enhance excitability.